A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

Neurology

Volumn 54, Issue 7, 2000, Pages 1414-1420

  Goodkin, Donald E ^a,h   Shulman, M ^b   Winkelhake, J ^b   Waubant, E ^a   Andersson, P B ^a   Stewart, T ^a   Nelson, S ^c   Fischbein, N ^c   Coyle, P K ^d   Frohman, E ^e   Jacobs, L ^f   Holcenberg, J ^b   Lee, M ^g   Mocci, S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

^g Intl Quantitative Consultants Inc   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AG284; Anergy; Clinical trials; MS; Myelin

Indexed keywords

AG 248; HLA DR2 ANTIGEN; MYELIN BASIC PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0034636191     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.7.1414     Document Type: Article

References (30)

1. Oksenberg JR, Hauser SL. Pathogenesis of multiple sclerosis: relationship to therapeutic strategies. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. London: Springer-Verlag, 1996:17-46.
2. Pette M, Fujita K, Kitze B, et al. MBP-specific T lymphocytes from MS patients and healthy donors. Neurology 1990;40: 1770-1776.
3. Salvetti M, Ristori G, D'Amato M, et al. Predominant and stable T cell responses to regions of MBP can be detected in individual patients with MS. Eur J Immunol 1993;23:1232-1239.
4. Sharma S, Nag B, Spack E, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex peptide complex. Proc Natl Acad Sci USA 1991;88:11405-11409.
5. Spack EG, Wehner NG, Winkelhake JL. Preclinical and pharmacological studies of AG284, a soluble HLA-DR2:myelin basic protein peptide complex for the treatment of multiple sclerosis. CNS Drug Rev 1998;4:225-246.
6. Tiwari JL, Terasaki PI, eds. HLA and disease associations. New York: Springer Verlag, 1985.
7. Olerup O, Hillert J. HLA class II associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991;38:1-15.
8. Pette M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990;87:7968-7972.
9. Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990;145:540-548.
10. Ota K, Matsui M, Milford E, Mackin G, Weiner H, Hafler D. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-187.
11. Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990;40:1770-1776.
12. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
15. Goodkin D, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improved assessment sensitivity with the use of the box & block and nine hole peg tests, Arch Physical Med Rehabil 1988;69:850-854.
16. Nelson SJ, Nalbandian AB, Proctor E, Vigneron DB. Registration of images from sequential MR examinations of the brain. J Magn Reson Imaging 1994;4:877-883.
17. McCutcheon M, Wehner N, Wensky A, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes J Immunol Methods 1997;210:149-166.
18. Phases of an Investigation, 21 CFR, Section 312.21. Washington, DC: US Government Printing Office, 1999.
19. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley & Sons, Inc., 1980:216-223.
20. Bretscher P, Cohen M. A theory of self-nonself discrimination. Science 1970;169:1042-1049.
21. Jenkins M, Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;65:302-319.
22. Quill H, Schwartz R. Stimulation of normal inducer T-cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987;138:3704-3712.
23. Nicolle M, Nag B, Sharma S, et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complex. J Clin Invest 1994;93:1361-1369.
24. Spack E, McCutcheon M, Corbelletta N, Nag B, Passmore D, Sharma S. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: acetylcholine receptor peptide complexes. J Autoimmunity 1995;8:787-807.
25. Stewart MA, Dunsavage MB, Islar J, Mukku P, Nag B, Reich E-P. Immunotherapy that prevents diabetes in NOD mice: soluble MHC class II + GAD 65 peptide. J Allergy Clin Immun 1997 (1 Pt 2):S117. Abstract.
26. Bertrams J, Kewurt E, Leidtke U. HLA antigens and multiple sclerosis. Tissue Antigens 1972;2:405-408.
27. Opelz G, Terasaki L, Myers G, et al. The association of HLA antigens A3, B7 and Duew2 with 330 multiple sclerosis patients in United States. Tissue Antigens 1977;9:54.
28. Valli A, Sette A, Kapos L, Oseroff C, et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993;91:616.
29. Mukku P, Passmore D, Phan D, Nag B. pH dependent binding of high and low affinity myelin basic protein peptides to purified HLA-DR2. Mol Immunol 1995;32:555-564.
30. Tuohy V, Yu M, Yin L, Kawczak J, Kinkel R. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 1999;189:1033-1042.